• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?

作者信息

Wojtukiewicz Marek Z, Pogorzelska Magda, Politynska Barbara

机构信息

Department of Oncology, Medical University of Bialystok, Bialystok, Poland.

Department of Clinical Oncology, Comprehensive Cancer Center, Bialystok, Poland.

出版信息

Cancer Metastasis Rev. 2022 Sep;41(3):465-469. doi: 10.1007/s10555-022-10060-4.

DOI:10.1007/s10555-022-10060-4
PMID:36066779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9470645/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a6c/9470645/fd14420e7558/10555_2022_10060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a6c/9470645/fd14420e7558/10555_2022_10060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a6c/9470645/fd14420e7558/10555_2022_10060_Fig1_HTML.jpg

相似文献

1
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?三阴性乳腺癌的免疫疗法：是起点的结束还是终点的开始？
Cancer Metastasis Rev. 2022 Sep;41(3):465-469. doi: 10.1007/s10555-022-10060-4.
2
Recent advances in triple negative breast cancer: the immunotherapy era.三阴性乳腺癌的最新进展：免疫治疗时代。
BMC Med. 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5.
3
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.三阴性乳腺癌的免疫治疗：现存挑战与振奋前景。
Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19.
4
Immunotherapy in triple-negative breast cancer.三阴性乳腺癌的免疫治疗。
Med Oncol. 2017 Dec 18;35(1):13. doi: 10.1007/s12032-017-1071-6.
5
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.组织因子作为三阴性乳腺癌 CAR-NK 细胞免疫治疗的新靶点。
Sci Rep. 2020 Feb 18;10(1):2815. doi: 10.1038/s41598-020-59736-3.
6
[Progress of Tumor Infiltrating Lymphocytes in Immunotherapy of Triple Negative Breast Cancer].[三阴性乳腺癌免疫治疗中肿瘤浸润淋巴细胞的研究进展]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021 Jun 30;43(3):475-480. doi: 10.3881/j.issn.1000-503X.12666.
7
Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.免疫疗法：三阴性乳腺癌治疗的新兴领域。
Cancer Lett. 2019 Feb 1;442:409-428. doi: 10.1016/j.canlet.2018.10.042. Epub 2018 Nov 9.
8
NICE allows immunotherapy treatment for small group of patients with advanced triple negative breast cancer.英国国家卫生与临床优化研究所允许对一小部分晚期三阴性乳腺癌患者进行免疫治疗。
BMJ. 2022 May 24;377:o1311. doi: 10.1136/bmj.o1311.
9
Recent advances in therapeutic strategies for triple-negative breast cancer.三阴性乳腺癌治疗策略的最新进展。
J Hematol Oncol. 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0.
10
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.D-甘露糖通过降解 PD-L1 促进三阴性乳腺癌的免疫治疗和放疗。
Proc Natl Acad Sci U S A. 2022 Feb 22;119(8). doi: 10.1073/pnas.2114851119.

引用本文的文献

1
Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer.乳腺癌中免疫检查点抑制剂反应和耐药的生物标志物。
Breast. 2025 Jul 21;83:104545. doi: 10.1016/j.breast.2025.104545.
2
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy.自体患者来源耗竭纳米 T 细胞利用肿瘤免疫逃逸来实施有效的癌症治疗。
Mol Cancer. 2024 May 9;23(1):83. doi: 10.1186/s12943-024-01997-x.
3
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.

本文引用的文献

1
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.三阴性乳腺癌免疫治疗的进展与展望
Front Oncol. 2022 Jun 20;12:919072. doi: 10.3389/fonc.2022.919072. eCollection 2022.
2
Current Clinical Trial Landscape of OX40 Agonists.OX40 激动剂的当前临床试验格局。
Curr Oncol Rep. 2022 Jul;24(7):951-960. doi: 10.1007/s11912-022-01265-5. Epub 2022 Mar 29.
3
Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.黏蛋白1和黏蛋白16：癌症治疗的靶点
一种新型 Fc 工程化的组织蛋白酶 D 靶向抗体增强 ADCC，触发肿瘤浸润 NK 细胞募集，并改善紫杉醇和恩扎卢胺联合治疗三阴性乳腺癌的效果。
J Immunother Cancer. 2024 Jan 30;12(1):e007135. doi: 10.1136/jitc-2023-007135.
4
Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.患有免疫治疗武器的三阴性乳腺癌：最新进展和临床前景。
Med Oncol. 2022 Dec 15;40(1):48. doi: 10.1007/s12032-022-01922-6.
5
Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy.社论：三阴性乳腺癌：异质性、肿瘤微环境与靶向治疗
Front Oncol. 2022 Nov 21;12:1026566. doi: 10.3389/fonc.2022.1026566. eCollection 2022.
Pharmaceuticals (Basel). 2021 Oct 17;14(10):1053. doi: 10.3390/ph14101053.
4
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.抗血管生成疗法可逆转免疫抑制性乳腺癌微环境。
Biomark Res. 2021 Jul 22;9(1):59. doi: 10.1186/s40364-021-00312-w.
5
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
6
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer.LAG-3 表达在三阴性乳腺癌中的预后和临床病理相关性。
Appl Immunohistochem Mol Morphol. 2022 Jan 1;30(1):62-71. doi: 10.1097/PAI.0000000000000954.
7
Leveraging epigenetics to enhance the efficacy of immunotherapy.利用表观遗传学提高免疫疗法的疗效。
Clin Epigenetics. 2021 May 17;13(1):115. doi: 10.1186/s13148-021-01100-x.
8
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2 breast cancer stem-like cells.抗 GD2 抗体 dinutuximab 通过靶向 GD2 乳腺癌干细胞样细胞抑制三阴性乳腺癌肿瘤生长。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001197.
9
Immunotherapy in Triple-Negative Breast Cancer.三阴性乳腺癌的免疫治疗。
Cancer J. 2021;27(1):59-66. doi: 10.1097/PPO.0000000000000497.
10
Triple‑negative breast cancer therapy: Current and future perspectives (Review).三阴性乳腺癌治疗：现状和未来展望（综述）。
Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16.